Freitag 24. November 2017

15.30 16.00 Registration and Reception
16.00 17.00CHAIR: R. GREIL, C. ZIELINSKI
16.00 16.10 Welcome R. Ott, C. Zielinski
16.10 16.35 Cancer therapy in 2017: transformation from palliative to curative setting R. Greil
16.35 16.55Achievements and milestones of oncology C. Zielinski
16.55 17.10 Challenges to overcome by future therapies K. Harrington
17.10 17.15Transfer to indication specific workshop rooms
17.15 18.15 Problem solving and decision making for IO therapies
Indication specific workshops:
  • Lung cancer: O. Burghuber, K. Vermaelen
  • Bladder cancer: M.O. Grimm, K. Gust
18.15 18.30 Break
18.30 19.00 Indication specific workshops – wrap up O. Burghuber, M.O. Grimm, K. Gust, K. Vermaelen
19.00 20.00 CHAIR: G. HÖFLER
19.00 19.30Molecular imaging derived predictive and early response biomarkers during IO treatment A.J. de Langen
Moderator: G. Höfler
Panel: W. Berger, R. Greil, K. Harrington
19.30 20.00New biomarker concepts for immunotherapy W. Berger
Moderator: G. Höfler
Panel: A.J. de Langen, R. Greil, K. Harrington
20.00 Dinner

Samstag 25. November 2017

09.00 10.00 CHAIR: R. GREIL
09.00 09.30What are the differences between PD-1 / PD-L1 antibodies? H. Sitte
Moderator: R. Greil
Discussion Panel: A.J. de Langen, K. Harrington, K. Vermaelen
09.30 10.00 Future concepts to enhance antitumor immunity R. Wilkinson
Moderator: R. Greil
Discussion Panel: A.J. de Langen, K. Harrington, H. Sitte, K. Vermaelen
10.00 10.30 Break
10.30 12.30CHAIR: C. ZIELINSKI
10.30 10.50 Crucial considerations for clinical trial design R. Pirker
10.50 12.00 Failed clinical trials – lessons and implications
M. De Santis (Imvigor 211), K. Harrington (Keynote 40), K. Vermaelen (Checkmate 26)
Moderator: C. Zielinski
Discussion Panel: M. De Santis, K. Gust, K. Harrington, K. Vermaelen
12.00 12.25 Opportunities and challenges of novel IO combinations M. De Santis
Moderator: C. Zielinski
Discussion Panel: K. Gust, K. Harrington, K. Vermaelen
12.25 12.30 Closing remarks C. Zielinski
12.30 Lunch